{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-024022","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.587651+00:00","generated_at":"2026-06-04T13:18:38.356050+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relmada reports FY 2023 net loss of $98.8M; advancing Phase 3 MDD trials with data expected H2 2024","bullets":["Q4 2023 net loss $25.2M ($0.84/share) vs $37.9M ($1.28) in Q4 2022; full-year net loss $98.8M ($3.28/share).","Cash, equivalents and short-term investments at Dec 31, 2023: $96.3M, down from $148.3M a year earlier.","R&D expense fell to $54.8M in FY 2023 from $113.3M in FY 2022, reflecting completion of prior Phase 3 trials.","REL-1017 Phase 3 Reliance II enrollment on track; top-line data expected H2 2024; Relight enrollment targeted by year-end 2024.","REL-P11 psilocybin Phase 1 in obese patients expected H1 2024; Phase 2a proof-of-concept data seen H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-024022","json":"https://secwatch.observer/filing/0001213900-24-024022.json","markdown":"https://secwatch.observer/filing/0001213900-24-024022.md","text":"https://secwatch.observer/filing/0001213900-24-024022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/0001213900-24-024022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/ea0202135-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:18:38.356050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0994bd844ce3bbaf30487ceec3625cbd1c140634","claim":"RELMADA THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: net income $98.8 million, EPS $3.28 per basic and diluted share.","evidence_excerpt":"Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fourth quarter and full year ended December 31, 2023. (These results are preliminary and unaudited.)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/0001213900-24-024022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"$98.8 million"},{"label":"EPS","value":"$3.28 per basic and diluted share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"0994bd844ce3bbaf30487ceec3625cbd1c140634","claim":"RELMADA THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: net income $98.8 million, EPS $3.28 per basic and diluted share.","evidence_excerpt":"Net loss for the year ended December 31, 2023 and 2022 was $98.8 million and $157.0 million, respectively. The Company had a net loss of $3.28 and $5.30 per basic and diluted share for the year ended December 31, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/0001213900-24-024022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"$98.8 million"},{"label":"EPS","value":"$3.28 per basic and diluted share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}